Capricor Therapeutics Director Sells Over $1.6 Million in Shares

Insider selling raises concerns about near-term outlook despite positive analyst sentiment

Apr. 4, 2026 at 10:28am

Got story updates? Submit your updates here. ›

Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar sold a total of 122,529 shares of the company's stock over the past few days, totaling over $1.6 million in transactions. This significant insider selling has raised concerns among investors about the company's near-term outlook, despite positive analyst sentiment and price target increases.

Why it matters

Insider selling, especially by directors and other key figures, can be a concerning signal to investors about a company's future prospects, even if the trades are executed under pre-arranged plans. This level of insider selling may raise questions about Capricor's short-term outlook, despite the positive analyst coverage and price targets.

The details

Karimah Es Sabar, a director at Capricor Therapeutics, sold a total of 122,529 shares of the company's stock over the past few days. The shares were sold at an average price ranging from $30.17 to $32.00, resulting in total proceeds of over $1.6 million. This includes a 7,529 share sale executed under a pre-arranged 10b5-1 trading plan, as well as larger block sales of 61,265 shares and 53,735 shares on March 31 and April 1, respectively.

On March 31, Karimah Es Sabar sold 61,265 shares at an average price of $30.17.
On April 1, Karimah Es Sabar sold 53,735 shares at an average price of $31.03.
On April 2, Karimah Es Sabar sold 7,529 shares at an average price of $32.00 under a pre-arranged 10b5-1 trading plan.

The players

Karimah Es Sabar

A director at Capricor Therapeutics who sold a significant number of shares over the past few days.